The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Quest Diagnostics Posts Strong Q4, Boosts Dividends & Buyback Amidst Selling Activity

Quest Diagnostics (DGX) reported robust fourth-quarter results, exceeding analyst expectations for both earnings per share and revenue. The diagnostic information services company also unveiled a significant $1.0 billion stock repurchase plan, signaling confidence in its future outlook. Further enhancing shareholder value, DGX announced an increase in its quarterly dividend. However, these positive developments were tempered by notable selling activity from key stakeholders. Cookson Peirce & Co. Inc. reduced its stake by 3.6%, selling 6,032 shares, while CEO J.E. Davis also divested a substantial number of company shares. This confluence of strong financial performance and strategic capital allocation alongside institutional and insider selling presents a mixed picture for investors.